HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

Inclusion Criteria: * Male and female subjects aged ≥2 years with CHI with persistent hypoglycemia despite current SoC treatment according to the investigator's evaluation or documentation * Stable therapy with SoC medications with or without nutritional supplementation * Previously undergone near-total pancreatectomy or being treated with a nonsurgical approach, having been evaluated as not eligible for pancreatic surgery * HbA1c \<7% Exclusion Criteria: * Subjects with type 1 or type 2 diabetes mellitus * Other reasons for hypoglycemia, including but not limited to drug-induced hyperinsulinemic hypoglycemia, etc * Treatment of CHI with continuous intravenous glucose or glucagon infusion within 3 months prior to screening * Subjects with current use of any drugs that are known to interfere with the study drug, glucose metabolism, or study procedures (eg, use of systemic glucocorticoids \[excluding topical, intra-articular or ophthalmic application, nasal spray, or inhaled forms\] or insulin) * Have conditions that could affect glucose levels such as pheochromocytoma, insulinoma, and glucagonoma